WEREWOLF THERAPEUTICS INC (HOWL)

US95075A1079 - Common Stock

6.26  +0.02 (+0.32%)

Fundamental Rating

2

HOWL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While HOWL seems to be doing ok healthwise, there are quite some concerns on its profitability. HOWL is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

HOWL had negative earnings in the past year.
HOWL had a negative operating cash flow in the past year.
In the past 5 years HOWL always reported negative net income.
HOWL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of HOWL (-21.38%) is better than 80.72% of its industry peers.
The Return On Equity of HOWL (-33.56%) is better than 79.35% of its industry peers.
Industry RankSector Rank
ROA -21.38%
ROE -33.56%
ROIC N/A
ROA(3y)-55.86%
ROA(5y)-56.17%
ROE(3y)-69.9%
ROE(5y)-85.47%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

HOWL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

HOWL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HOWL has been increased compared to 1 year ago.
HOWL has a worse debt/assets ratio than last year.

2.2 Solvency

HOWL has an Altman-Z score of -0.03. This is a bad value and indicates that HOWL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.03, HOWL is in the better half of the industry, outperforming 60.41% of the companies in the same industry.
A Debt/Equity ratio of 0.29 indicates that HOWL is not too dependend on debt financing.
HOWL has a worse Debt to Equity ratio (0.29) than 70.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -0.03
ROIC/WACCN/A
WACC9.34%

2.3 Liquidity

A Current Ratio of 7.14 indicates that HOWL has no problem at all paying its short term obligations.
The Current ratio of HOWL (7.14) is better than 68.94% of its industry peers.
A Quick Ratio of 7.14 indicates that HOWL has no problem at all paying its short term obligations.
HOWL's Quick ratio of 7.14 is fine compared to the rest of the industry. HOWL outperforms 68.94% of its industry peers.
Industry RankSector Rank
Current Ratio 7.14
Quick Ratio 7.14

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.68% over the past year.
Looking at the last year, HOWL shows a very strong growth in Revenue. The Revenue has grown by 21.59%.
EPS 1Y (TTM)44.68%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q15.38%
Revenue 1Y (TTM)21.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-79.38%

3.2 Future

HOWL is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.30% yearly.
The Revenue is expected to grow by 26.30% on average over the next years. This is a very strong growth
EPS Next Y-29.13%
EPS Next 2Y-10.44%
EPS Next 3Y-9.71%
EPS Next 5Y-5.3%
Revenue Next Year-71.39%
Revenue Next 2Y-12.87%
Revenue Next 3Y-6.49%
Revenue Next 5Y26.3%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HOWL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HOWL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as HOWL's earnings are expected to decrease with -9.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.44%
EPS Next 3Y-9.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HOWL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WEREWOLF THERAPEUTICS INC

NASDAQ:HOWL (5/1/2024, 10:19:20 AM)

6.26

+0.02 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap271.37M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.38%
ROE -33.56%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.14
Quick Ratio 7.14
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)44.68%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-29.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.59%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y